IA regimen as the induction chemotherapy in treatment of acute myeloid leukemia (AML): a multi-center, randomised clinical trial

INTERVENTION: Group A:Idarubicin 8mg/ m2, intravenously administration daily for 3 days;Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours);Group B:Idarubicin 10mg/ m2, intravenously administration daily for 3 days;Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) daily for 7days; CONDITION: acute myeloid leukemia (AML) PRIMARY OUTCOME: complete remission; SECONDARY OUTCOME: desease free suvival;2‐year ovrall survival;relapse free survival; INCLUSION CRITERIA: 1. Male and female aged 18 to 60 years old; 2. Able and willing to provide signed informed consent; 3. De novo AML (excluding M3); 4. Normal function of liver and kidney: serum total bilirubin <=35umol/L; AST/ALT < 2.0*upper limit of normal (ULN); 5. Normal cardiac function; 6. ECOG performance status of 0,1 or 2 (WHO standard).